New Diabetes Technology: What to Expect in 2023

The field of diabetes management has been undergoing significant advancements in recent years, and 2023 promises to be an exciting year with several groundbreaking technologies on the horizon. These innovations aim to enhance the lives of individuals living with diabetes, providing them with better tools for monitoring their blood sugar levels, managing their condition, and improving overall health outcomes.

Continuous Glucose Monitoring (CGM) systems have revolutionized diabetes management by offering real-time data on glucose levels. In 2023, one can anticipate even more advanced CGM systems that provide enhanced accuracy, longer wear times, and improved user experience. These systems will not only measure glucose levels but also provide valuable insights into trends, patterns, and predictive analytics, allowing individuals with diabetes to make proactive decisions about their treatment and lifestyle choices.
The 66th Annual Meeting of the Japan Diabetes Society will feature the Dexcom G6 CGM, according to an announcement from Dexcom. After the release of the G7, the G6 is currently the company's CGM from a prior generation. It makes use of a tiny, wearable sensor. Additionally, it has a transmitter that continuously monitors and wirelessly transmits glucose levels to a smart device or receiver. People with diabetes can use the technology to get real-time glucose information without having to scan or prick their fingers.
Artificial Pancreas Systems, also known as closed-loop systems, are designed to automate insulin delivery and closely mimic the function of a healthy pancreas. These systems utilize advanced algorithms and continuous glucose monitoring to adjust insulin doses in real-time, based on the individual's glucose levels. Comparing individuals in a control group who continued to rely on the methods they were currently using to manage their blood sugar, trial participants utilising the artificial pancreas spent almost three more hours per day in their target blood sugar range. For example, Tandem Diabetes Care makes the Control-IQ system, a diabetes care tool that automatically detects and controls blood glucose. When necessary, the insulin dose is adjusted by the artificial pancreas' insulin pump using sophisticated control algorithms based on the user's glucose monitoring data. In 2023, we can expect further refinements in artificial pancreas technology, including improved accuracy, better integration with mobile devices, and increased availability for different age groups, such as children and adolescents.
The year 2023 will witness advancements in insulin delivery devices, making them smarter, more user-friendly, and more convenient for individuals with diabetes. We can anticipate the introduction of more discreet and comfortable insulin pumps with advanced features such as automated insulin dosing based on glucose readings. Additionally, innovations in insulin pen technologies will offer improved dose accuracy, connectivity options for data tracking, and user-friendly interfaces. As per BioIntel360, the market size by insulin pens is expected to record a CAGR of 15.2% during 2023-2027 to reach US$7,251.1 million by 2027, increasing from US$4,120.6 million in 2023. Over the last five years, the sector has recorded a CAGR of 14.9% to reach US$3,551.6 million in 2022.
Digital health solutions will continue to play a significant role in diabetes management in 2023. Mobile applications, connected devices, and remote monitoring platforms will enable individuals with diabetes to track their blood sugar levels, log insulin doses and meals, receive personalized insights, and communicate with their healthcare providers seamlessly. These solutions will empower patients to take control of their condition and foster better communication and collaboration between patients and healthcare teams.
Advancements in genetics and precision medicine are opening doors to personalized therapies for diabetes management. In 2023, we can expect further developments in this field, with innovative therapies targeted to specific patient subgroups based on their genetic profile, lifestyle factors, and treatment response. Precision medicine approaches will allow for more effective and tailored treatments, reducing the burden of diabetes and improving patient outcomes.
Clinical decision support systems leverage artificial intelligence and machine learning algorithms to assist healthcare providers in making informed decisions about diabetes management. These systems analyze vast amounts of patient data, including glucose levels, insulin doses, medication history, and other relevant parameters, to provide personalized treatment recommendations. One can anticipate more sophisticated and accurate clinical decision support systems that integrate seamlessly into electronic health records, enhancing the efficiency and quality of diabetes care.

BioIntel360 suggests that the advancements in diabetes technology expected in 2023 hold great promise for individuals living with diabetes. These innovations aim to empower patients, improve glycemic control, and enhance the overall quality of life for those managing this chronic condition.